Researchers find potential drug treatment targets for alcohol-related liver disease

May 19, 2020

Alcohol-related liver disease (ALD) is a deadly condition affecting more than 150 million people worldwide with no treatment available besides transplant.

But now, a team led by researchers from Massachusetts General Hospital (MGH) has uncovered key molecular step stones in ALD that may provide targets for drug therapy development. Their work was recently published in Proceedings of the National Academy of Sciences (PNAS).

This groundbreaking research was achieved by combining RNA sequence analysis of patient liver samples with transgenic mouse studies.

The team identified two promising potential molecular targets for ALD drug development - cGAS and Cx32. The lead author on the study is Jay Luther, MD, gastroenterologist and Director of the Mass General Alcohol Liver Center. The senior author is Suraj J. Patel, MD, PhD, a research fellow in the department of Medicine.

"Now that we know the key players in this pathway, we finally have drug targets for treatment development," says Luther. "Until now, we haven't had any successful leads. Meanwhile, the number of patients has grown."

Researchers already knew that liver cell (hepatocyte) death in ALD is driven by IFN regulatory factor (IRF3). That process also fuels a strong secondary inflammatory response that affects nearby cells and can eventually lead to liver failure.

But scientists have been puzzling over how alcohol activates IRF3 and which pathways amplify the inflammatory signals that make the disease spread throughout the liver. As a result of that process, ALD attacks the liver at a certain point regardless of whether the patient is still drinking alcohol.

"Until now, now we had only few clues about why alcohol-related liver disease progresses the way it does, but this research fills in key pieces of the puzzle," says Patel.

In their studies, the team analyzed liver cells from patients, with a wide range in degree of disease severity, using RNA-sequencing. Their analysis showed that the level of cGAS expression was related to the degree of disease.

In a study of alcohol-fed mice, they found those animals also had higher expression of the cGAS-IrF3 pathway in liver cells. Meanwhile, mice that were genetically designed to have lower levels of cGAS and IRF3 were less susceptible to ALD.

The Mass General-led team determined that cytoplasmic sensor cyclic guanosine monophosphate-adenosine monophosphate (AMP) synthase (cGAS) drives IRF3 activation in both liver cells directly injured by alcohol as well as neighboring cells. They also pinpointed connexin 32 (Cx32) as a possible new drug target, as it is a key regulator of cGAS-driven IRF3 activation.

"It is very encouraging to see that we now have evidence-based targets for drug development for ALD," says Luther.
-end-
About the Massachusetts General Hospital Alcohol Liver Center

The Mass General Alcohol Liver Center strives to advance the care of patients with alcohol-related liver disease, a leading cause of liver disease, through clinical and research innovation. The center takes a comprehensive, multidisciplinary approach to the clinical care of patients with alcohol-related liver disease. The team consists of liver specialists (hepatologists), addiction medicine physicians, specialized nurses, transplant liver physicians and social workers, all of whom work together to provide the best possible to care our patients. Additionally, the center is also dedicated to research advancing the understanding of the causes of alcohol-related liver disease and improving therapies to prevent and treat alcohol-related liver disease. The research program spans the spectrum of clinical, translational and basic science work and includes prominent investigators committed to defeating this disease.

About the Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of over $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2019, the Mass General was named #2 in the U.S. News & World Report list of "America's Best Hospitals."

Massachusetts General Hospital

Related Alcohol Articles from Brightsurf:

Alcohol use changed right after COVID-19 lockdown
One in four adults reported a change in alcohol use almost immediately after stay-at-home orders were issued: 14% reported drinking more alcohol and reported higher levels of stress and anxiety than those who did not drink and those whose use stayed the same.

Changes in hospitalizations for alcohol use disorder in US
Changes over nearly two decades in the rate of hospitalizations and in-hospital deaths from alcohol use disorder in the US were examined in this study.

Associations of alcohol consumption, alcohol-induced passing out with risk of dementia
The risk of future dementia associated with overall alcohol consumption and alcohol-induced loss of consciousness in a population of current drinkers was examined in this observational study with more than 131,000 adults.

New alcohol genes uncovered
Do you have what is known as problematic alcohol use?

Does estrogen influence alcohol use disorder?
A new study from researchers at the University of Illinois at Chicago shows that high estrogen levels may make alcohol more rewarding to female mice.

Sobering new data on drinking and driving: 15% of US alcohol-related motor vehicle fatalities involve alcohol under the legal limit
A new study in the American Journal of Preventive Medicine, published by Elsevier, found that motor vehicle crashes involving drivers with blood alcohol concentrations (BACs) below the legal limit of 0.08 percent accounted for 15% of alcohol-involved crash deaths in the United States.

Alcohol-induced deaths in US
National vital statistics data from 2000 to 2016 were used to examine how rates of alcohol-induced deaths (defined as those deaths due to alcohol consumption that could be avoided if alcohol weren't involved) have changed in the US and to compare the results by demographic groups including sex, race/ethnicity, age, socioeconomic status and geographic location.

Cuts in alcohol duty linked to 2000 more alcohol-related deaths in England
Government cuts to alcohol taxes have had dramatic consequences for public health, including nearly 2000 more alcohol-related deaths in England since 2012, according to new research from the University of Sheffield's School of Health and Related Research (ScHARR).

Integrated stepped alcohol treatment for people in HIV care improves both HIV & alcohol outcomes
Increasing the intensity of treatment for alcohol use disorder (AUD) over time improves alcohol-related outcomes among people with HIV, according to new clinical research supported by the National Institutes of Health.

The Lancet:Targets to reduce harmful alcohol use are likely to be missed as global alcohol intake increases
Increasing rates of alcohol use suggest that the world is not on track to achieve targets against harmful alcohol use, according to a study of 189 countries' alcohol intake between 1990-2017 and estimated intake up to 2030, published in The Lancet.

Read More: Alcohol News and Alcohol Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.